Please login to the form below
chronic lung disease
This page shows the latest chronic lung disease news and features for those working in and with pharma, biotech and healthcare.
FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
All participants in this trial had at least one risk factor for developing severe COVID-19, including chronic lung disease, obesity, cardiovascular disease or were at least 50 years of age. ... high-risk of severe disease or hospitalisation.
Latest news
-
Detailed results for Regeneron's antibody cocktail continue to show benefit in high-risk COVID-19 outpatients
All participants in this trial had at least one risk factor for developing severe COVID-19, including chronic lung disease, obesity, cardiovascular disease or were at least 50 years of age. ... In the US, REGEN-COV is authorised for emergency use to
-
AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial
palivizumab) among preterm infants and children with chronic lung disease (CLD) and congenital heart disease (CHD).
-
Roche’s flu pill Xofluza gains EU approval
This includes influenza patients who have conditions including asthma, chronic lung disease, diabetes, heart disease or morbid obesity or adults aged 65 and over.
-
Moderna’s COVID-19 vaccine could offer protection for ‘a couple of years’, says CEO
On Wednesday, the European Commission granted Moderna’s COVID-19 vaccine, initially called mRNA-1273, a conditional marketing authorisation to prevent the disease in people aged 18 years and older. ... The trial also showed a 90.9% efficacy rate in
-
Moderna wins EU authorisation for COVID-19 vaccine
The trial also showed a 90.9% efficacy rate in participants who were at risk of developing severe COVID-19 infection, including people with chronic lung disease, heart disease, obesity, liver ... disease, diabetes or HIV infection.
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
Latest from PMHub
-
October 2020: diversity and inclusion in clinical trials round-up
People with chronic conditions such as diabetes, lung disease, and heart disease, and those of advanced age, had a poorer prognosis once infected with COVID-19. ... In the U.S., fewer healthcare providers have training, knowledge, and expertise in
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- A creative awakening – how pharma is bringing innovation to the patient journey
- How Resonant’s innovation and creativity resolve healthcare communications challenges
- The pharma dichotomy
- Our Top 5 Pharma Picks From Cannes Lions
- Live Webinar: Streamlining the Drug Development Process to Transform Global Health
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- Pfizer, Mylan move ahead with generics merger and spin-out
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- Roche shares new positive Ocrevus data for MS patients
PMHub
M3 (EU)
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
